The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / IV Meloxicam Stalls at FDA; Plus Health Canada Approves Risankizumab for Plaque Psoriasis

IV Meloxicam Stalls at FDA; Plus Health Canada Approves Risankizumab for Plaque Psoriasis

May 14, 2019 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

FDA Sends Second Complete Response Letter for Intravenous Meloxicam
The U.S. Food and Drug Administration (FDA) has sent a second complete response letter to Recro Pharma regarding the new drug application for intravenous (IV) meloxicam. The treatment is designed to manage moderate to severe pain.1

You Might Also Like
  • Revised Application Expected for IV Meloxicam; Plus EU Approves Tildrakizumab
  • Risankizumab Promising for Psoriasis; Plus Canada Approves Brodalumab
  • FDA Approves Risankizumab, Adds Stronger Warning to Sleep Medications
Explore This Issue
June 2019
Also By This Author
  • Upadacitinib Promising for RA in Phase 3 Study

The letter cited the onset and duration of IV meloxicam as concerns, noting that the delayed onset fails to meet the prescriber expectations for IV drugs. The letter also cited regulatory concerns about the role of IV meloxicam as a monotherapy for acute pain, as well as how it would meet patient and prescriber needs in that setting.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Recro Pharma intends to continue to pursue regulatory approval for IV meloxicam. The manufacturer was disappointed by the letter and is dedicated to bringing IV meloxicam and other non-opioid pain products to market. Recro Pharma will work closely with the FDA to determine the best path forward.

Canada Approves Risankizumab
In April, risankizumab (Skyrizi) was approved in Canada for treating adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.2 Risankizumab is a humanized immunoglobulin monoclonal antibody designed to selectively inhibit IL-23 by binding to its p19 subunit. The treatment was first approved in late March in Japan.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In clinical trials, risankizumab significantly improved skin level clearance after 16 weeks, which was maintained up to one year (52 weeks). This approval was based on results from these aforementioned clinical trials with dosing every three months in more than 2,000 patients. Canadians living with moderate to severe plaque psoriasis were well represented in these pivotal clinical trials, leading to Health Canada’s approval.

During the trials, the most common adverse effects were upper respiratory infections, tinea infections, headache, pruritus, fatigue and injection site reactions.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Recro Pharma Inc. News release: Recro Pharma receives complete response letter from the FDA for intravenous meloxicam. 2019 Mar 22.
  2. Abbvie Inc. News release: Health Canada approves Skyrizi (risankizumab) for the treatment of moderate to severe plaque psoriasis. 2019 Apr 18.

Filed Under: Analgesics, Biologics & Biosimilars, Drug Updates Tagged With: Canada, FDA, meloxicam, non-opioid pain shot, Pain, plaque psoriasis, rizankixumab, U.S. Food and Drug Administration (FDA)Issue: June 2019

You Might Also Like:
  • Revised Application Expected for IV Meloxicam; Plus EU Approves Tildrakizumab
  • Risankizumab Promising for Psoriasis; Plus Canada Approves Brodalumab
  • FDA Approves Risankizumab, Adds Stronger Warning to Sleep Medications
  • IV Tramadol Promising for Postoperative Pain; FDA Denies IV Meloxicam Approval

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)